Drug Profile


Alternative Names: Adcirca; Cialis; GF 196960; IC 351; LY 450190; Zalutia

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator GlaxoSmithKline; ICOS Corporation
  • Developer Eli Lilly; Gilead Sciences; GlaxoSmithKline; ICOS Corporation; Northwestern University; United Therapeutics Corporation
  • Class Antihypertensives; Benzodioxoles; Carbolines; Erectile dysfunction therapies; Indoles; Pyridones; Small molecules; Vasodilators
  • Mechanism of Action Type 5 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Benign prostatic hyperplasia; Erectile dysfunction; Pulmonary arterial hypertension
  • Phase III Duchenne muscular dystrophy
  • Clinical Phase Unknown Raynaud's disease
  • Discontinued Angina pectoris; Female sexual dysfunction; Gastroparesis; Heart failure

Most Recent Events

  • 22 Aug 2017 Eli Lilly enters into a settlement agreement with Argentum Pharmaceuticals related to marketing of generic Tadalafil
  • 12 Jul 2017 Eli Lilly enters into settlement agreement with generic companies related to a patent covering tadalafil unit dose in USA
  • 15 Mar 2016 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top